Detail Information of Xenobiotics

General Information of Xenobiotics (ID: XEO00009)
Xenobiotics Name
Bicalutamide
Xenobiotics Type
Pharmaceutical Agent(s)
Classification
Approved/Marketed Drug
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=2375"></iframe>
3D MOL 2D MOL
PubChem CID
2375
DME(s) Modulated by This Xenobiotics
DME(s) Inhibited by This Xenobiotics
Butyrylcholine esterase (BCHE) DME Info Homo sapiens [1]
Thymidylate synthase (TYMS) DME Info Homo sapiens [2]
UDP-glucuronosyltransferase 2B17 (UGT2B17) DME Info Homo sapiens [1]
DME(s) Induced by This Xenobiotics
Neprilysin (MME) DME Info Homo sapiens [3]
Uridine phosphorylase 1 (UPP1) DME Info Homo sapiens [1]
References
1 Microarray analysis of bicalutamide action on telomerase activity, p53 pathway and viability of prostate carcinoma cell lines. J Pharm Pharmacol. 2005 Jan;57(1):83-92.
2 Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer. Oncogene. 2007 Dec 6;26(55):7611-9.
3 Casodex treatment induces hypoxia-related gene expression in the LNCaP prostate cancer progression model. BMC Urol. 2005 Mar 24;5:5.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.